Hikma Pharmaceuticals PLC (H5P.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 09:49PM CEST
| Previous Close | 22.60 |
| Open | 22.60 |
| Bid | 23.00 x N/A |
| Ask | 23.40 x N/A |
| Day's Range | 22.60 - 23.00 |
| 52 Week Range | 19.70 - 25.60 |
| Volume | |
| Avg. Volume | 1 |
| Market Cap | 5.103B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 28.40 |
| EPS (TTM) | 0.81 |
| Earnings Date | Feb 22, 2024 |
| Forward Dividend & Yield | 0.66 (2.94%) |
| Ex-Dividend Date | Mar 21, 2024 |
| 1y Target Est | N/A |
Simply Wall St.With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
- Simply Wall St.
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Reuters
Merck's Bridion faces generic threat from drugmaker Hikma
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.
© 2024 Yahoo. All rights reserved.